Download PDF
Thromb Haemost 2018; 118(07): 1141-1166
DOI: 10.1055/s-0038-1654714
Review Article
Georg Thieme Verlag KG Stuttgart · New York

The Lectin Pathway in Thrombotic Conditions—A Systematic Review

Julie Brogaard Larsen
1   Centre for Haemophilia and Thrombosis, Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark
,
Christine Lodberg Hvas
2   Department of Anaesthesiology and Intensive Care Medicine, Randers Regional Hospital, Randers, Denmark
,
Anne-Mette Hvas
1   Centre for Haemophilia and Thrombosis, Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark
3   Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
› Author Affiliations Funding J.B.L. was supported by a grant from the Faculty of Health, Aarhus University and the Health Research Fund of the Central Denmark Region.
Further Information

Publication History

26 October 2017

12 April 2018

Publication Date:
04 June 2018 (online)

Also available at
   Permissions and Reprints

Abstract

The lectin pathway of the complement system can activate the coagulation system in vitro, but the role of the lectin pathway in haemostatic activation and thrombosis in vivo is not clear. We performed a systematic review of the existing literature on associations between the lectin pathway and arterial and venous thrombosis, in accordance with the Assessing the Methodological Quality of Systematic Reviews guidelines. PubMed and Embase were searched from January 1990 to March 2017. We included original studies on human study populations investigating associations between the lectin pathway (protein serum levels, genotype or gene expression) and thrombotic conditions or laboratory coagulation markers. Exclusion criteria were case studies including fewer than five cases, conference abstracts or any other language than English. In total, 43 studies were included which investigated associations between the lectin pathway and cardiovascular thrombotic events (CVEs) (n = 22), ischaemic stroke (n = 9), CVE and stroke (n = 1) and other conditions (systemic lupus erythematosus [n = 6], sepsis-related coagulopathy [n = 3], pulmonary embolism [n = 1], asparaginase treatment [n = 1]). Studies on the lectin pathway and CVE risk reported discrepant results, as both high and low mannose-binding lectin (MBL) serum levels were found to correlate with increased CVE risk. In ischaemic stroke patients, occurrence of stroke as well as increased stroke severity and poor outcome were consistently associated with high serum MBL. For other thromboembolic conditions, only few studies were identified. In conclusion, lectin pathway activation may negatively influence outcome after ischaemic stroke and possibly contribute to CVE risk. Further research is warranted to elucidate the role of the lectin pathway in other thrombotic conditions.

Keywords

lectin pathway - complement proteins - mannose-binding lectin - thromboembolism - blood coagulation
 

  • References

  • 1 Esmon CT, Xu J, Lupu F. Innate immunity and coagulation. J Thromb Haemost 2011; 9 (Suppl. 01) 182-188
    CrossrefPubMedGoogle Scholar
  • 2 van der Poll T, Herwald H. The coagulation system and its function in early immune defense. Thromb Haemost 2014; 112 (04) 640-648
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Oikonomopoulou K, Ricklin D, Ward PA, Lambris JD. Interactions between coagulation and complement--their role in inflammation. Semin Immunopathol 2012; 34 (01) 151-165
    CrossrefPubMedGoogle Scholar
  • 4 Degn SE, Jensenius JC, Bjerre M. The lectin pathway and its implications in coagulation, infections and auto-immunity. Curr Opin Organ Transplant 2011; 16 (01) 21-27
    CrossrefPubMedGoogle Scholar
  • 5 Degn SE, Thiel S, Jensenius JC. New perspectives on mannan-binding lectin-mediated complement activation. Immunobiology 2007; 212 (4-5): 301-311
    CrossrefPubMedGoogle Scholar
  • 6 Garred P, Genster N, Pilely K. , et al. A journey through the lectin pathway of complement-MBL and beyond. Immunol Rev 2016; 274 (01) 74-97
    CrossrefPubMedGoogle Scholar
  • 7 Matsushita M, Endo Y, Fujita T. Structural and functional overview of the lectin complement pathway: its molecular basis and physiological implication. Arch Immunol Ther Exp (Warsz) 2013; 61 (04) 273-283
    CrossrefPubMedGoogle Scholar
  • 8 Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res 2010; 20 (01) 34-50
    CrossrefPubMedGoogle Scholar
  • 9 Ma YJ, Doni A, Hummelshøj T. , et al. Synergy between ficolin-2 and pentraxin 3 boosts innate immune recognition and complement deposition. J Biol Chem 2009; 284 (41) 28263-28275
    CrossrefPubMedGoogle Scholar
  • 10 Ma YJ, Doni A, Skjoedt MO. , et al. Heterocomplexes of mannose-binding lectin and the pentraxins PTX3 or serum amyloid P component trigger cross-activation of the complement system. J Biol Chem 2011; 286 (05) 3405-3417
    CrossrefPubMedGoogle Scholar
  • 11 Ng PM, Le Saux A, Lee CM. , et al. C-reactive protein collaborates with plasma lectins to boost immune response against bacteria. EMBO J 2007; 26 (14) 3431-3440
    CrossrefPubMedGoogle Scholar
  • 12 Zhang J, Yang L, Ang Z. , et al. Secreted M-ficolin anchors onto monocyte transmembrane G protein-coupled receptor 43 and cross talks with plasma C-reactive protein to mediate immune signaling and regulate host defense. J Immunol 2010; 185 (11) 6899-6910
    CrossrefPubMedGoogle Scholar
  • 13 Frederiksen PD, Thiel S, Larsen CB, Jensenius JC. M-ficolin, an innate immune defence molecule, binds patterns of acetyl groups and activates complement. Scand J Immunol 2005; 62 (05) 462-473
    CrossrefPubMedGoogle Scholar
  • 14 Matsushita M, Endo Y, Fujita T. Cutting edge: complement-activating complex of ficolin and mannose-binding lectin-associated serine protease. J Immunol 2000; 164 (05) 2281-2284
    CrossrefPubMedGoogle Scholar
  • 15 Luo F, Sun X, Wang Y. , et al. Ficolin-2 defends against virulent mycobacteria tuberculosis infection in vivo, and its insufficiency is associated with infection in humans. PLoS One 2013; 8 (09) e73859
    CrossrefPubMedGoogle Scholar
  • 16 Thiel S, Holmskov U, Hviid L, Laursen SB, Jensenius JC. The concentration of the C-type lectin, mannan-binding protein, in human plasma increases during an acute phase response. Clin Exp Immunol 1992; 90 (01) 31-35
    PubMedGoogle Scholar
  • 17 Dean MM, Minchinton RM, Heatley S, Eisen DP. Mannose binding lectin acute phase activity in patients with severe infection. J Clin Immunol 2005; 25 (04) 346-352
    CrossrefPubMedGoogle Scholar
  • 18 Plovsing RR, Berg RM, Munthe-Fog L. , et al. Alveolar recruitment of ficolin-3 in response to acute pulmonary inflammation in humans. Immunobiology 2016; 221 (05) 690-697
    CrossrefPubMedGoogle Scholar
  • 19 Van Till JW, Boermeester MA, Modderman PW. , et al. Variable mannose-binding lectin expression during postoperative acute-phase response. Surg Infect (Larchmt) 2006; 7 (05) 443-452
    CrossrefPubMedGoogle Scholar
  • 20 Ytting H, Christensen IJ, Basse L. , et al. Influence of major surgery on the mannan-binding lectin pathway of innate immunity. Clin Exp Immunol 2006; 144 (02) 239-246
    CrossrefPubMedGoogle Scholar
  • 21 Troldborg A, Hansen A, Hansen SW, Jensenius JC, Stengaard-Pedersen K, Thiel S. Lectin complement pathway proteins in healthy individuals. Clin Exp Immunol 2017; 188 (01) 138-147
    CrossrefPubMedGoogle Scholar
  • 22 Thiel S. Complement activating soluble pattern recognition molecules with collagen-like regions, mannan-binding lectin, ficolins and associated proteins. Mol Immunol 2007; 44 (16) 3875-3888
    CrossrefPubMedGoogle Scholar
  • 23 Bronkhorst MW, Lomax MA, Vossen RH, Bakker J, Patka P, van Lieshout EM. Risk of infection and sepsis in severely injured patients related to single nucleotide polymorphisms in the lectin pathway. Br J Surg 2013; 100 (13) 1818-1826
    CrossrefPubMedGoogle Scholar
  • 24 De Pascale G, Cutuli SL, Pennisi MA, Antonelli M. The role of mannose-binding lectin in severe sepsis and septic shock. Mediators Inflamm 2013; 2013: 625803
    PubMedGoogle Scholar
  • 25 Eisen DP, Dean MM, Thomas P. , et al. Low mannose-binding lectin function is associated with sepsis in adult patients. FEMS Immunol Med Microbiol 2006; 48 (02) 274-282
    CrossrefPubMedGoogle Scholar
  • 26 Schlapbach LJ, Mattmann M, Thiel S. , et al. Differential role of the lectin pathway of complement activation in susceptibility to neonatal sepsis. Clin Infect Dis 2010; 51 (02) 153-162
    CrossrefPubMedGoogle Scholar
  • 27 Charchaflieh J, Rushbrook J, Worah S, Zhang M. Activated complement factors as disease markers for sepsis. Dis Markers 2015; 2015: 382463
    PubMedGoogle Scholar
  • 28 Munthe-Fog L, Hummelshøj T, Honoré C, Madsen HO, Permin H, Garred P. Immunodeficiency associated with FCN3 mutation and ficolin-3 deficiency. N Engl J Med 2009; 360 (25) 2637-2644
    CrossrefPubMedGoogle Scholar
  • 29 Metzger ML, Michelfelder I, Goldacker S. , et al. Low ficolin-2 levels in common variable immunodeficiency patients with bronchiectasis. Clin Exp Immunol 2015; 179 (02) 256-264
    CrossrefPubMedGoogle Scholar
  • 30 Schlapbach LJ, Thiel S, Kessler U, Ammann RA, Aebi C, Jensenius JC. Congenital H-ficolin deficiency in premature infants with severe necrotising enterocolitis. Gut 2011; 60 (10) 1438-1439
    CrossrefPubMedGoogle Scholar
  • 31 Boldt AB, Luz PR, Messias-Reason IJ. MASP2 haplotypes are associated with high risk of cardiomyopathy in chronic Chagas disease. Clin Immunol 2011; 140 (01) 63-70
    CrossrefPubMedGoogle Scholar
  • 32 Boldt AB, Goeldner I, Stahlke ER, Thiel S, Jensenius JC, de Messias-Reason IJ. Leprosy association with low MASP-2 levels generated by MASP2 haplotypes and polymorphisms flanking MAp19 exon 5. PLoS One 2013; 8 (07) e69054
    CrossrefPubMedGoogle Scholar
  • 33 Munye MM, Diaz-Font A, Ocaka L. , et al. COLEC10 is mutated in 3MC patients and regulates early craniofacial development. PLoS Genet 2017; 13 (03) e1006679
    CrossrefPubMedGoogle Scholar
  • 34 Rooryck C, Diaz-Font A, Osborn DP. , et al. Mutations in lectin complement pathway genes COLEC11 and MASP1 cause 3MC syndrome. Nat Genet 2011; 43 (03) 197-203
    CrossrefPubMedGoogle Scholar
  • 35 Sirmaci A, Walsh T, Akay H. , et al. MASP1 mutations in patients with facial, umbilical, coccygeal, and auditory findings of Carnevale, Malpuech, OSA, and Michels syndromes. Am J Hum Genet 2010; 87 (05) 679-686
    CrossrefPubMedGoogle Scholar
  • 36 Jacobsen S, Garred P, Madsen HO. , et al. Mannose-binding lectin gene polymorphisms are associated with disease activity and physical disability in untreated, anti-cyclic citrullinated peptide-positive patients with early rheumatoid arthritis. J Rheumatol 2009; 36 (04) 731-735
    CrossrefPubMedGoogle Scholar
  • 37 Troelsen LN, Garred P, Jacobsen S. Mortality and predictors of mortality in rheumatoid arthritis--a role for mannose-binding lectin?. J Rheumatol 2010; 37 (03) 536-543
    CrossrefPubMedGoogle Scholar
  • 38 Ammitzboll CG, Thiel S, Ellingsen T. , et al. Levels of lectin pathway proteins in plasma and synovial fluid of rheumatoid arthritis and osteoarthritis. Rheumatol Int 2012; 32 (05) 1457-1463
    CrossrefPubMedGoogle Scholar
  • 39 Epp Boschmann S, Goeldner I, Tuon FF, Schiel W, Aoyama F, de Messias-Reason IJ. Mannose-binding lectin polymorphisms and rheumatoid arthritis: a short review and meta-analysis. Mol Immunol 2016; 69: 77-85
    CrossrefPubMedGoogle Scholar
  • 40 Troldborg A, Thiel S, Laska MJ, Deleuran B, Jensenius JC, Stengaard-Pedersen K. Levels in plasma of the serine proteases and associated proteins of the lectin pathway are altered in patients with systemic lupus erythematosus. J Rheumatol 2015; 42 (06) 948-951
    CrossrefPubMedGoogle Scholar
  • 41 Hein E, Nielsen LA, Nielsen CT. , et al. Ficolins and the lectin pathway of complement in patients with systemic lupus erythematosus. Mol Immunol 2015; 63 (02) 209-214
    CrossrefPubMedGoogle Scholar
  • 42 Jenny L, Ajjan R, King R, Thiel S, Schroeder V. Plasma levels of mannan-binding lectin-associated serine proteases MASP-1 and MASP-2 are elevated in type 1 diabetes and correlate with glycaemic control. Clin Exp Immunol 2015; 180 (02) 227-232
    CrossrefPubMedGoogle Scholar
  • 43 Axelgaard E, Østergaard JA, Thiel S, Hansen TK. Diabetes is associated with increased autoreactivity of mannan-binding lectin. J Diabetes Res 2017; 2017: 6368780
    PubMedGoogle Scholar
  • 44 Best LG, Davidson M, North KE. , et al. Prospective analysis of mannose-binding lectin genotypes and coronary artery disease in American Indians: the Strong Heart Study. Circulation 2004; 109 (04) 471-475
    CrossrefPubMedGoogle Scholar
  • 45 Hertle E, Arts IC, van der Kallen CJ. , et al. Distinct longitudinal associations of MBL, MASP-1, MASP-2, MASP-3, and MAp44 with endothelial dysfunction and intima-media thickness: the Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) Study. Arterioscler Thromb Vasc Biol 2016; 36 (06) 1278-1285
    CrossrefPubMedGoogle Scholar
  • 46 Ytting H, Christensen IJ, Thiel S, Jensenius JC, Nielsen HJ. Pre- and postoperative levels in serum of mannan-binding lectin associated serine protease-2 -a prognostic marker in colorectal cancer. Hum Immunol 2008; 69 (07) 414-420
    CrossrefPubMedGoogle Scholar
  • 47 Storm L, Christensen IJ, Jensenius JC, Nielsen HJ, Thiel S. ; Danish Study Group on Early Detection of Colorectal Cancer. Evaluation of complement proteins as screening markers for colorectal cancer. Cancer Immunol Immunother 2015; 64 (01) 41-50
    CrossrefPubMedGoogle Scholar
  • 48 Swierzko AS, Szala A, Sawicki S. , et al. Mannose-binding lectin (MBL) and MBL-associated serine protease-2 (MASP-2) in women with malignant and benign ovarian tumours. Cancer Immunol Immunother 2014; 63 (11) 1129-1140
    CrossrefPubMedGoogle Scholar
  • 49 Ambrus G, Gál P, Kojima M. , et al. Natural substrates and inhibitors of mannan-binding lectin-associated serine protease-1 and -2: a study on recombinant catalytic fragments. J Immunol 2003; 170 (03) 1374-1382
    CrossrefPubMedGoogle Scholar
  • 50 Presanis JS, Hajela K, Ambrus G, Gál P, Sim RB. Differential substrate and inhibitor profiles for human MASP-1 and MASP-2. Mol Immunol 2004; 40 (13) 921-929
    CrossrefPubMedGoogle Scholar
  • 51 Dobó J, Harmat V, Beinrohr L, Sebestyén E, Závodszky P, Gál P. MASP-1, a promiscuous complement protease: structure of its catalytic region reveals the basis of its broad specificity. J Immunol 2009; 183 (02) 1207-1214
    CrossrefPubMedGoogle Scholar
  • 52 Krarup A, Gulla KC, Gál P, Hajela K, Sim RB. The action of MBL-associated serine protease 1 (MASP1) on factor XIII and fibrinogen. Biochim Biophys Acta 2008; 1784 (09) 1294-1300
    CrossrefPubMedGoogle Scholar
  • 53 Hess K, Ajjan R, Phoenix F, Dobó J, Gál P, Schroeder V. Effects of MASP-1 of the complement system on activation of coagulation factors and plasma clot formation. PLoS One 2012; 7 (04) e35690
    CrossrefPubMedGoogle Scholar
  • 54 Hajela K, Kojima M, Ambrus G. , et al. The biological functions of MBL-associated serine proteases (MASPs). Immunobiology 2002; 205 (4-5): 467-475
    CrossrefPubMedGoogle Scholar
  • 55 Gulla KC, Gupta K, Krarup A. , et al. Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot. Immunology 2010; 129 (04) 482-495
    CrossrefPubMedGoogle Scholar
  • 56 Jenny L, Dobó J, Gál P, Schroeder V. MASP-1 induced clotting--the first model of prothrombin activation by MASP-1. PLoS One 2015; 10 (12) e0144633
    CrossrefPubMedGoogle Scholar
  • 57 Jenny L, Dobó J, Gál P, Schroeder V. MASP-1 of the complement system promotes clotting via prothrombin activation. Mol Immunol 2015; 65 (02) 398-405
    CrossrefPubMedGoogle Scholar
  • 58 Jenny L, Dobó J, Gál P, Pál G, Lam WA, Schroeder V. MASP-1 of the complement system enhances clot formation in a microvascular whole blood flow model. PLoS One 2018; 13 (01) e0191292
    CrossrefPubMedGoogle Scholar
  • 59 Krarup A, Wallis R, Presanis JS, Gál P, Sim RB. Simultaneous activation of complement and coagulation by MBL-associated serine protease 2. PLoS One 2007; 2 (07) e623
    CrossrefPubMedGoogle Scholar
  • 60 Endo Y, Nakazawa N, Iwaki D, Takahashi M, Matsushita M, Fujita T. Interactions of ficolin and mannose-binding lectin with fibrinogen/fibrin augment the lectin complement pathway. J Innate Immun 2010; 2 (01) 33-42
    CrossrefPubMedGoogle Scholar
  • 61 Kozarcanin H, Lood C, Munthe-Fog L. , et al. The lectin complement pathway serine proteases (MASPs) represent a possible crossroad between the coagulation and complement systems in thromboinflammation. J Thromb Haemost 2016; 14 (03) 531-545
    CrossrefPubMedGoogle Scholar
  • 62 Keizer MP, Pouw RB, Kamp AM. , et al. TFPI inhibits lectin pathway of complement activation by direct interaction with MASP-2. Eur J Immunol 2015; 45 (02) 544-550
    CrossrefPubMedGoogle Scholar
  • 63 AMSTAR-Assessing the Methodological Quality of Systematic Reviews; 2015. Available at: https://amstar.ca/ . Accessed August 29, 2017
    PubMed
  • 64 Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies; 2014. Available at: https://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/tools/cohort . Accessed May 1, 2017
    PubMed
  • 65 Quality Assessment of Case-Control Studies; 2014. Available at: https://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/tools/case-control
    PubMed
  • 66 Poppelaars F, Gaya da Costa M, Berger SP. , et al. Strong predictive value of mannose-binding lectin levels for cardiovascular risk of hemodialysis patients. J Transl Med 2016; 14 (01) 236
    CrossrefPubMedGoogle Scholar
  • 67 Siezenga MA, Shaw PK, Daha MR, Rabelink TJ, Berger SP. Low mannose-binding lectin (MBL) genotype is associated with future cardiovascular events in type 2 diabetic South Asians. A prospective cohort study. Cardiovasc Diabetol 2011; 10: 60
    CrossrefPubMedGoogle Scholar
  • 68 Troelsen LN, Garred P, Madsen HO, Jacobsen S. Genetically determined high serum levels of mannose-binding lectin and agalactosyl IgG are associated with ischemic heart disease in rheumatoid arthritis. Arthritis Rheum 2007; 56 (01) 21-29
    CrossrefPubMedGoogle Scholar
  • 69 Berger SP, Roos A, Mallat MJ. , et al. Low pretransplantation mannose-binding lectin levels predict superior patient and graft survival after simultaneous pancreas-kidney transplantation. J Am Soc Nephrol 2007; 18 (08) 2416-2422
    CrossrefPubMedGoogle Scholar
  • 70 Keller TT, van Leuven SI, Meuwese MC. , et al. Serum levels of mannose-binding lectin and the risk of future coronary artery disease in apparently healthy men and women. Arterioscler Thromb Vasc Biol 2006; 26 (10) 2345-2350
    CrossrefPubMedGoogle Scholar
  • 71 Saevarsdottir S, Oskarsson OO, Aspelund T. , et al. Mannan binding lectin as an adjunct to risk assessment for myocardial infarction in individuals with enhanced risk. J Exp Med 2005; 201 (01) 117-125
    CrossrefPubMedGoogle Scholar
  • 72 Vengen IT, Madsen HO, Garred P, Platou C, Vatten L, Videm V. Mannose-binding lectin deficiency is associated with myocardial infarction: the HUNT2 study in Norway. PLoS One 2012; 7 (07) e42113
    CrossrefPubMedGoogle Scholar
  • 73 Vengen IT, Enger TB, Videm V, Garred P. Pentraxin 3, ficolin-2 and lectin pathway associated serine protease MASP-3 as early predictors of myocardial infarction - the HUNT2 study. Sci Rep 2017; 7: 43045
    CrossrefPubMedGoogle Scholar
  • 74 Pesonen E, Hallman M, Sarna S. , et al. Mannose-binding lectin as a risk factor for acute coronary syndromes. Ann Med 2009; 41 (08) 591-598
    CrossrefPubMedGoogle Scholar
  • 75 Hansen TK, Tarnow L, Thiel S. , et al. Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes 2004; 53 (06) 1570-1576
    CrossrefPubMedGoogle Scholar
  • 76 Zhang M, Hou YJ, Cavusoglu E. , et al. MASP-2 activation is involved in ischemia-related necrotic myocardial injury in humans. Int J Cardiol 2013; 166 (02) 499-504
    CrossrefPubMedGoogle Scholar
  • 77 Mellbin LG, Hamsten A, Malmberg K. , et al. Mannose-binding lectin genotype and phenotype in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Diabetes Care 2010; 33 (11) 2451-2456
    CrossrefPubMedGoogle Scholar
  • 78 Trendelenburg M, Theroux P, Stebbins A, Granger C, Armstrong P, Pfisterer M. Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Eur Heart J 2010; 31 (10) 1181-1187
    CrossrefPubMedGoogle Scholar
  • 79 Haahr-Pedersen S, Bjerre M, Flyvbjerg A. , et al. Level of complement activity predicts cardiac dysfunction after acute myocardial infarction treated with primary percutaneous coronary intervention. J Invasive Cardiol 2009; 21 (01) 13-19
    PubMedGoogle Scholar
  • 80 Collard CD, Shernan SK, Fox AA. , et al. The MBL2 ‘LYQA secretor’ haplotype is an independent predictor of postoperative myocardial infarction in whites undergoing coronary artery bypass graft surgery. Circulation 2007; 116 (11, Suppl): I106-I112
    PubMedGoogle Scholar
  • 81 Ueland T, Espevik T, Kjekshus J. , et al. Mannose binding lectin and soluble Toll-like receptor 2 in heart failure following acute myocardial infarction. J Card Fail 2006; 12 (08) 659-663
    CrossrefPubMedGoogle Scholar
  • 82 Limnell V, Aittoniemi J, Vaarala O. , et al. Association of mannan-binding lectin deficiency with venous bypass graft occlusions in patients with coronary heart disease. Cardiology 2002; 98 (03) 123-126
    CrossrefPubMedGoogle Scholar
  • 83 Schoos MM, Munthe-Fog L, Skjoedt MO. , et al. Association between lectin complement pathway initiators, C-reactive protein and left ventricular remodeling in myocardial infarction-a magnetic resonance study. Mol Immunol 2013; 54 (3-4): 408-414
    CrossrefPubMedGoogle Scholar
  • 84 Holt CB, Thiel S, Munk K, Østergaard JA, Bøtker HE, Hansen TK. Association between endogenous complement inhibitor and myocardial salvage in patients with myocardial infarction. Eur Heart J Acute Cardiovasc Care 2014; 3 (01) 3-9
    CrossrefPubMedGoogle Scholar
  • 85 Mellbin LG, Bjerre M, Thiel S, Hansen TK. Complement activation and prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Diabetes Care 2012; 35 (04) 911-917
    CrossrefPubMedGoogle Scholar
  • 86 Kouchaki E, Babamohammadi A, Nikoueinejad H, Sehat M. Association of serum levels of pentraxin-3, M-ficolin, and surfactant protein A with the severity of ischemic stroke. Iran J Allergy Asthma Immunol 2017; 16 (02) 140-146
    PubMedGoogle Scholar
  • 87 Huang J, Ma X, Li Q. , et al. Serum mannose-binding lectin levels in patients with ischemic stroke. Int J Clin Exp Med 2016; 9 (08) 16332-16338
    PubMedGoogle Scholar
  • 88 Zangari R, Zanier ER, Torgano G. , et al; LEPAS group. Early ficolin-1 is a sensitive prognostic marker for functional outcome in ischemic stroke. J Neuroinflammation 2016; 13: 16
    CrossrefPubMedGoogle Scholar
  • 89 Song FY, Wu MH, Zhu LH, Zhang ZQ, Qi QD, Lou CL. Elevated serum mannose-binding lectin levels are associated with poor outcome after acute ischemic stroke in patients with type 2 diabetes. Mol Neurobiol 2015; 52 (03) 1330-1340
    CrossrefPubMedGoogle Scholar
  • 90 Zhang ZG, Wang C, Wang J. , et al. Prognostic value of mannose-binding lectin: 90-day outcome in patients with acute ischemic stroke. Mol Neurobiol 2015; 51 (01) 230-239
    CrossrefPubMedGoogle Scholar
  • 91 Wang ZY, Sun ZR, Zhang LM. The relationship between serum mannose-binding lectin levels and acute ischemic stroke risk. Neurochem Res 2014; 39 (02) 248-253
    CrossrefPubMedGoogle Scholar
  • 92 Füst G, Munthe-Fog L, Illes Z. , et al. Low ficolin-3 levels in early follow-up serum samples are associated with the severity and unfavorable outcome of acute ischemic stroke. J Neuroinflammation 2011; 8: 185
    CrossrefPubMedGoogle Scholar
  • 93 Osthoff M, Katan M, Fluri F. , et al. Mannose-binding lectin deficiency is associated with smaller infarction size and favorable outcome in ischemic stroke patients. PLoS One 2011; 6 (06) e21338
    CrossrefPubMedGoogle Scholar
  • 94 Cervera A, Planas AM, Justicia C. , et al. Genetically-defined deficiency of mannose-binding lectin is associated with protection after experimental stroke in mice and outcome in human stroke. PLoS One 2010; 5 (02) e8433
    CrossrefPubMedGoogle Scholar
  • 95 Frauenknecht V, Thiel S, Storm L. , et al. Plasma levels of mannan-binding lectin (MBL)-associated serine proteases (MASPs) and MBL-associated protein in cardio- and cerebrovascular diseases. Clin Exp Immunol 2013; 173 (01) 112-120
    CrossrefPubMedGoogle Scholar
  • 96 Jönsen A, Gullstrand B, Güner N. , et al. Genetically determined mannan-binding lectin deficiency is of minor importance in determining susceptibility to severe infections and vascular organ damage in systemic lupus erythematosus. Lupus 2007; 16 (04) 245-253
    CrossrefPubMedGoogle Scholar
  • 97 Font J, Ramos-Casals M, Brito-Zerón P. , et al. Association of mannose-binding lectin gene polymorphisms with antiphospholipid syndrome, cardiovascular disease and chronic damage in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2007; 46 (01) 76-80
    CrossrefPubMedGoogle Scholar
  • 98 Calvo-Alén J, Alarcón GS, Tew MB. , et al; LUMINA Study Group. Systemic lupus erythematosus in a multiethnic US cohort: XXXIV. Deficient mannose-binding lectin exon 1 polymorphisms are associated with cerebrovascular but not with other arterial thrombotic events. Arthritis Rheum 2006; 54 (06) 1940-1945
    CrossrefPubMedGoogle Scholar
  • 99 Øhlenschlaeger T, Garred P, Madsen HO, Jacobsen S. Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. N Engl J Med 2004; 351 (03) 260-267
    CrossrefPubMedGoogle Scholar
  • 100 Lv W, Wang L, Duan Q. , et al. Characteristics of the complement system gene expression deficiency in patients with symptomatic pulmonary embolism. Thromb Res 2013; 132 (01) e54-e57
    CrossrefPubMedGoogle Scholar
  • 101 Merlen C, Bonnefoy A, Wagner E. , et al. L-Asparaginase lowers plasma antithrombin and mannan-binding-lectin levels: impact on thrombotic and infectious events in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2015; 62 (08) 1381-1387
    CrossrefPubMedGoogle Scholar
  • 102 Takahashi K, Ohtani K, Larvie M. , et al. Elevated plasma CL-K1 level is associated with a risk of developing disseminated intravascular coagulation (DIC). J Thromb Thrombolysis 2014; 38 (03) 331-338
    CrossrefPubMedGoogle Scholar
  • 103 Sprong T, Mollnes TE, Neeleman C. , et al. Mannose-binding lectin is a critical factor in systemic complement activation during meningococcal septic shock. Clin Infect Dis 2009; 49 (09) 1380-1386
    CrossrefPubMedGoogle Scholar
  • 104 Zhao X, Chen YX, Li CS. Predictive value of the complement system for sepsis-induced disseminated intravascular coagulation in septic patients in emergency department. J Crit Care 2015; 30 (02) 290-295
    CrossrefPubMedGoogle Scholar
  • 105 Pavlov VI, Skjoedt MO, Siow Tan Y, Rosbjerg A, Garred P, Stahl GL. Endogenous and natural complement inhibitor attenuates myocardial injury and arterial thrombogenesis. Circulation 2012; 126 (18) 2227-2235
    CrossrefPubMedGoogle Scholar
  • 106 Takahashi K, Chang WC, Takahashi M. , et al. Mannose-binding lectin and its associated proteases (MASPs) mediate coagulation and its deficiency is a risk factor in developing complications from infection, including disseminated intravascular coagulation. Immunobiology 2011; 216 (1-2): 96-102
    CrossrefPubMedGoogle Scholar
  • 107 de la Rosa X, Cervera A, Kristoffersen AK. , et al. Mannose-binding lectin promotes local microvascular thrombosis after transient brain ischemia in mice. Stroke 2014; 45 (05) 1453-1459
    CrossrefPubMedGoogle Scholar
  • 108 Fumagalli S, De Simoni MG. Lectin complement pathway and its bloody interactions in brain ischemia. Stroke 2016; 47 (12) 3067-3073
    CrossrefPubMedGoogle Scholar
  • 109 Jordan JE, Montalto MC, Stahl GL. Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury. Circulation 2001; 104 (12) 1413-1418
    CrossrefPubMedGoogle Scholar
  • 110 Hart ML, Ceonzo KA, Shaffer LA. , et al. Gastrointestinal ischemia-reperfusion injury is lectin complement pathway dependent without involving C1q. J Immunol 2005; 174 (10) 6373-6380
    CrossrefPubMedGoogle Scholar
  • 111 Busche MN, Pavlov V, Takahashi K, Stahl GL. Myocardial ischemia and reperfusion injury is dependent on both IgM and mannose-binding lectin. Am J Physiol Heart Circ Physiol 2009; 297 (05) H1853-H1859
    CrossrefPubMedGoogle Scholar
  • 112 Ducruet AF, Sosunov SA, Zacharia BE. , et al. The neuroprotective effect of genetic mannose-binding lectin deficiency is not sustained in the sub-acute phase of stroke. Transl Stroke Res 2011; 2 (04) 588-599
    CrossrefPubMedGoogle Scholar
  • 113 Orsini F, Villa P, Parrella S. , et al. Targeting mannose-binding lectin confers long-lasting protection with a surprisingly wide therapeutic window in cerebral ischemia. Circulation 2012; 126 (12) 1484-1494
    CrossrefPubMedGoogle Scholar
  • 114 Orsini F, Chrysanthou E, Dudler T. , et al. Mannan binding lectin-associated serine protease-2 (MASP-2) critically contributes to post-ischemic brain injury independent of MASP-1. J Neuroinflammation 2016; 13 (01) 213
    CrossrefPubMedGoogle Scholar
  • 115 Walsh MC, Bourcier T, Takahashi K. , et al. Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J Immunol 2005; 175 (01) 541-546
    CrossrefPubMedGoogle Scholar
  • 116 La Bonte LR, Dokken B, Davis-Gorman G, Stahl GL, McDonagh PF. The mannose-binding lectin pathway is a significant contributor to reperfusion injury in the type 2 diabetic heart. Diab Vasc Dis Res 2009; 6 (03) 172-180
    CrossrefPubMedGoogle Scholar
  • 117 Schwaeble WJ, Lynch NJ, Clark JE. , et al. Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury. Proc Natl Acad Sci U S A 2011; 108 (18) 7523-7528
    CrossrefPubMedGoogle Scholar
  • 118 Pant S, Deshmukh A, Gurumurthy GS. , et al. Inflammation and atherosclerosis--revisited. J Cardiovasc Pharmacol Ther 2014; 19 (02) 170-178
    CrossrefPubMedGoogle Scholar
  • 119 Viola J, Soehnlein O. Atherosclerosis - a matter of unresolved inflammation. Semin Immunol 2015; 27 (03) 184-193
    CrossrefPubMedGoogle Scholar
  • 120 Langer HF, Gawaz M. Platelet-vessel wall interactions in atherosclerotic disease. Thromb Haemost 2008; 99 (03) 480-486
    Article in Thieme ConnectPubMedGoogle Scholar
  • 121 Lisman T. Platelet-neutrophil interactions as drivers of inflammatory and thrombotic disease. Cell Tissue Res 2018; 371 (03) 567-576
    CrossrefPubMedGoogle Scholar
  • 122 Pilely K, Rosbjerg A, Genster N. , et al. Cholesterol crystals activate the lectin complement pathway via ficolin-2 and mannose-binding lectin: implications for the progression of atherosclerosis. J Immunol 2016; 196 (12) 5064-5074
    CrossrefPubMedGoogle Scholar
  • 123 Vazquez-Garza E, Jerjes-Sanchez C, Navarrete A, Joya-Harrison J, Rodriguez D. Venous thromboembolism: thrombosis, inflammation, and immunothrombosis for clinicians. J Thromb Thrombolysis 2017; 44 (03) 377-385
    CrossrefPubMedGoogle Scholar
  • 124 Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. Semin Thromb Hemost 2013; 39 (05) 559-566
    Article in Thieme ConnectPubMedGoogle Scholar
  • 125 Takase S, Schmid-Schönbein G, Bergan JJ. Leukocyte activation in patients with venous insufficiency. J Vasc Surg 1999; 30 (01) 148-156
    CrossrefPubMedGoogle Scholar
  • 126 Takase S, Bergan JJ, Schmid-Schönbein G. Expression of adhesion molecules and cytokines on saphenous veins in chronic venous insufficiency. Ann Vasc Surg 2000; 14 (05) 427-435
    CrossrefPubMedGoogle Scholar
  • 127 Ekdahl KN, Teramura Y, Hamad OA. , et al. Dangerous liaisons: complement, coagulation, and kallikrein/kinin cross-talk act as a linchpin in the events leading to thromboinflammation. Immunol Rev 2016; 274 (01) 245-269
    CrossrefPubMedGoogle Scholar
  • 128 Gabriel DA, Muga K, Boothroyd EM. The effect of fibrin structure on fibrinolysis. J Biol Chem 1992; 267 (34) 24259-24263
    CrossrefPubMedGoogle Scholar
  • 129 Litzman J, Freiberger T, Grimbacher B. , et al. Mannose-binding lectin gene polymorphic variants predispose to the development of bronchopulmonary complications but have no influence on other clinical and laboratory symptoms or signs of common variable immunodeficiency. Clin Exp Immunol 2008; 153 (03) 324-330
    CrossrefPubMedGoogle Scholar
  • 130 Luo J, Xu F, Lu GJ, Lin HC, Feng ZC. Low mannose-binding lectin (MBL) levels and MBL genetic polymorphisms associated with the risk of neonatal sepsis: an updated meta-analysis. Early Hum Dev 2014; 90 (10) 557-564
    CrossrefPubMedGoogle Scholar
  • 131 Peterslund NA, Koch C, Jensenius JC, Thiel S. Association between deficiency of mannose-binding lectin and severe infections after chemotherapy. Lancet 2001; 358 (9282): 637-638
    CrossrefPubMedGoogle Scholar
  • 132 Mullighan CG, Heatley S, Doherty K. , et al. Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation. Blood 2002; 99 (10) 3524-3529
    CrossrefPubMedGoogle Scholar
  • 133 Garcia-Laorden MI, Sole-Violan J, Rodriguez de Castro F. , et al. Mannose-binding lectin and mannose-binding lectin-associated serine protease 2 in susceptibility, severity, and outcome of pneumonia in adults. J Allergy Clin Immunol 2008; 122 (02) 368-374 , 374.e1–374.e2
    CrossrefPubMedGoogle Scholar
  • 134 Kruse C, Rosgaard A, Steffensen R, Varming K, Jensenius JC, Christiansen OB. Low serum level of mannan-binding lectin is a determinant for pregnancy outcome in women with recurrent spontaneous abortion. Am J Obstet Gynecol 2002; 187 (05) 1313-1320
    CrossrefPubMedGoogle Scholar
  • 135 Christiansen OB, Kilpatrick DC, Souter V, Varming K, Thiel S, Jensenius JC. Mannan-binding lectin deficiency is associated with unexplained recurrent miscarriage. Scand J Immunol 1999; 49 (02) 193-196
    CrossrefPubMedGoogle Scholar
  • 136 Kilpatrick DC, Bevan BH, Liston WA. Association between mannan binding protein deficiency and recurrent miscarriage. Hum Reprod 1995; 10 (09) 2501-2505
    CrossrefPubMedGoogle Scholar
  • 137 Munthe-Fog L, Hummelshoj T, Honoré C. , et al. Variation in FCN1 affects biosynthesis of ficolin-1 and is associated with outcome of systemic inflammation. Genes Immun 2012; 13 (07) 515-522
    CrossrefPubMedGoogle Scholar
  • 138 Ammitzbøll CG, Kjær TR, Steffensen R. , et al. Non-synonymous polymorphisms in the FCN1 gene determine ligand-binding ability and serum levels of M-ficolin. PLoS One 2012; 7 (11) e50585
    CrossrefPubMedGoogle Scholar
  • 139 Boldt AB, Sanchez MI, Stahlke ER. , et al. Susceptibility to leprosy is associated with M-ficolin polymorphisms. J Clin Immunol 2013; 33 (01) 210-219
    CrossrefPubMedGoogle Scholar
  • 140 Munthe-Fog L, Hummelshøj T, Hansen BE. , et al. The impact of FCN2 polymorphisms and haplotypes on the Ficolin-2 serum levels. Scand J Immunol 2007; 65 (04) 383-392
    CrossrefPubMedGoogle Scholar
  • 141 Bayarri-Olmos R, Hansen S, Henriksen ML. , et al. Genetic variation of COLEC10 and COLEC11 and association with serum levels of collectin liver 1 (CL-L1) and collectin kidney 1 (CL-K1). PLoS One 2015; 10 (02) e0114883
    CrossrefPubMedGoogle Scholar
  • 142 Antony JS, Ojurongbe O, Kremsner PG, Velavan TP. Lectin complement protein Collectin 11 (CL-K1) and susceptibility to urinary schistosomiasis. PLoS Negl Trop Dis 2015; 9 (03) e0003647
    CrossrefPubMedGoogle Scholar
  • 143 Troegeler A, Lugo-Villarino G, Hansen S. , et al. Collectin CL-LK is a novel soluble pattern recognition receptor for mycobacterium tuberculosis. PLoS One 2015; 10 (07) e0132692
    CrossrefPubMedGoogle Scholar
  • 144 Beltrame MH, Boldt AB, Catarino SJ. , et al. MBL-associated serine proteases (MASPs) and infectious diseases. Mol Immunol 2015; 67 (01) 85-100
    CrossrefPubMedGoogle Scholar
  • 145 Stengaard-Pedersen K, Thiel S, Gadjeva M. , et al. Inherited deficiency of mannan-binding lectin-associated serine protease 2. N Engl J Med 2003; 349 (06) 554-560
    CrossrefPubMedGoogle Scholar
  • 146 Sokolowska A, Szala A, St Swierzko A. , et al. Mannan-binding lectin-associated serine protease-2 (MASP-2) deficiency in two patients with pulmonary tuberculosis and one healthy control. Cell Mol Immunol 2015; 12 (01) 119-121
    CrossrefPubMedGoogle Scholar
  • 147 García-Laorden MI, García-Saavedra A, de Castro FR. , et al. Low clinical penetrance of mannose-binding lectin-associated serine protease 2 deficiency. J Allergy Clin Immunol 2006; 118 (06) 1383-1386
    CrossrefPubMedGoogle Scholar
  • 148 Skjødt M-O, Munthe-Fog L, Hansen KM, Garred P. Inhibition of the coagulation system by the complement regulator MBL/Ficolin-Associated Protein-1 (MAP-1). Molecular Immunology 2014; 61 (02) 219
    PubMedGoogle Scholar